Peng Xiong, Yang Rui, Wang Christopher, Peng Weilin, Zhao Zhenyu, Shi Shuai, Cai Qidong, He Boxue, Wang Li, Yu Fenglei, Wang Xiang, Tao Yongguang
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China.
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China; Department of Pathology, School of Basic Medicine and Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Cancer Lett. 2025 Mar 31;613:217503. doi: 10.1016/j.canlet.2025.217503. Epub 2025 Jan 31.
YTHDF3-DT, a long non-coding RNA (lncRNA) significantly upregulated in lung adenocarcinoma (LUAD), is associated with poor patient prognosis and plays critical roles in LUAD progression. Clinical data and in vitro analyses revealed that YTHDF3-DT expression correlates with worse overall survival and increased lymph node metastasis in LUAD patients. Functional studies demonstrated that YTHDF3-DT activates the TGF-β and PI3K/Akt/mTOR signaling pathways via INHBA, a key target influenced by YTHDF3-DT. Mechanistically, YTHDF3-DT stabilizes INHBA mRNA by acting as a competing endogenous RNA (ceRNA) for miR-301a-3p, forming a YTHDF3-DT/miR-301a-3p/INHBA axis. This axis regulates ferroptosis in an autophagy-dependent manner in LUAD cells, with YTHDF3-DT promoting cell survival by altering autophagic activity and mitigating ferroptosis-induced cell death. In vivo experiments further validated the role of YTHDF3-DT in tumor growth and ferroptosis regulation, highlighting its potential as a therapeutic target in LUAD. Our data contribute toward a significant mechanistic understanding of the molecules involved in the crosstalk between ferroptosis and autophagy, providing potential therapeutic targets to complement the existing therapies for overcoming the developed resistance in patients with LUAD.
YTHDF3-DT是一种在肺腺癌(LUAD)中显著上调的长链非编码RNA(lncRNA),与患者预后不良相关,并在LUAD进展中起关键作用。临床数据和体外分析表明,YTHDF3-DT的表达与LUAD患者较差的总生存期和增加的淋巴结转移相关。功能研究表明,YTHDF3-DT通过INHBA激活TGF-β和PI3K/Akt/mTOR信号通路,INHBA是受YTHDF3-DT影响的关键靶点。从机制上讲,YTHDF3-DT通过作为miR-301a-3p的竞争性内源RNA(ceRNA)来稳定INHBA mRNA,形成YTHDF3-DT/miR-301a-3p/INHBA轴。该轴以自噬依赖性方式调节LUAD细胞中的铁死亡,YTHDF3-DT通过改变自噬活性和减轻铁死亡诱导的细胞死亡来促进细胞存活。体内实验进一步验证了YTHDF3-DT在肿瘤生长和铁死亡调节中的作用,突出了其作为LUAD治疗靶点的潜力。我们的数据有助于对参与铁死亡和自噬之间相互作用的分子有重要的机制理解,为补充现有疗法以克服LUAD患者产生的耐药性提供潜在的治疗靶点。